Seoul National University Hospital Hematology and Oncology Kim In-ho

Kim In-ho

Seoul National University Hospital|Hematology and Oncology

3.33 reviewsSeoul Jongno-gu

Last updated

Professor Kim In-ho provides care informed by warm clinical expertise and is trusted for careful explanations in the field of blood cancers, including chronic myeloid leukemia.

Medical opinions · Patient reviews3

3.3/ 5.0
Medical professional's opinion
GoodDoctorNet verified medical professional06/16/2024

환자의 의사를 그닥 존중해주지 않으십니다. 듣기 좋은 말만 해주시고 안 좋은 얘기는 전공의 시켜서 좋은 교수님이라는 평이 많은 거 같음

Medical professional's opinion
GoodDoctorNet verified medical professional12/17/2023

여러모로 환자를 편안하게 해주십니다. 실력이야 당연히 다른 이가 왈가왈부할 수준은 아득히 뛰어넘으신 분입니다. 다만 최신 지견에 맞춘 공격적인 항암 보다는 정립된 방식의 치료에 초점을 맞추시는 인상이 있습니다. 추천합니다.

Medical professional's opinion
GoodDoctorNet verified medical professional12/16/2023

세심한 지식을 가지고 환자들에게 매번 친절하게 진료해주시는 교수님

Ask other patients

If reviews don't answer your questions, ask patients and caregivers who have been there.

Hospital information

Address
101 Daehak-ro, Jongno-gu, Seoul
University
서울대학교 의과대학
Appointments
1588-5700Book by phone (1588-5700)
All doctors at Seoul National University Hospital

Education and career

Education

  • 2002–2006 Doctor of Medicine, Inha University Graduate School
  • 2000–2002 Master of Medicine, Department of Medicine, Seoul National University Graduate School
  • 1985–1992 Bachelor of Medicine, Department of Medicine, Seoul National University College of Medicine

Career

  • 2017 Professor, Seoul National University Hospital
  • 2007–2008 U.S. National Institute of Health
  • 2005–2017 Associate Professor, Seoul National University Hospital
  • 2001–2005 Instructor–Assistant Professor, Inha University Hospital
  • 2000–2001 Fellow, Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital
  • Title: Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study.
  • Publication: KOREAN JOURNAL OF INTERNAL MEDICINE
  • Publication date: 2021-1
  • PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/32279477/
  • Title: Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
  • Publication: LANCET ONCOLOGY
  • Publication date: 2020-2
  • PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/33129376/
  • Title: Preconditioning absolute lymphocyte count and transplantation outcomes in matched related donor allogeneic hematopoietic stem cell transplantation recipients with reduced-intensity conditioning and antithymocyte globulin treatment.
  • Publication: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
  • Publication date: 2020-0
  • PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/32561338/
  • Title: High cell-free DNA levels in cerebrospinal fluid predict leptomeningeal seeding of hematologic malignancy.
  • Publication: JOURNAL OF CLINICAL NEUROLOGY
  • Publication date: 2020-0
  • PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/33029963/
  • Title: Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies.
  • Publication: KOREAN JOURNAL OF INTERNAL MEDICINE
  • Publication date: 2020-9
  • PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/31487770/

FAQ

What conditions does Kim In-ho treat?
Kim In-ho (Hematology and Oncology, Seoul National University Hospital) treats conditions such as Leukemia, Myelodysplastic syndrome, Multiple myeloma, Myeloproliferative neoplasms, Anemia/Platelet disorders.
Where does Kim In-ho see patients?
In Hematology and Oncology at Seoul National University Hospital. The hospital address is 101 Daehak-ro, Jongno-gu, Seoul.
What is Kim In-ho's patient rating?
3.3 out of 5, based on ratings from 3 patients who were actually treated.
What is Kim In-ho's specialty?
Specialty: Hematology and Oncology.

Is any information wrong?

Let us know about changes to hospital, specialty, career and so on, and we'll update it after checking.